Emmaus Life Sciences, Inc.
EMMA · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $1 | $1 | $1 |
| + Debt | $32 | $32 | $33 | $33 |
| Enterprise Value | $32 | $32 | $33 | $32 |
| Revenue | $3 | $3 | $2 | $3 |
| % Growth | 19.9% | 17.1% | -26.9% | – |
| Gross Profit | $3 | $3 | $2 | $3 |
| % Margin | 92.7% | 94.7% | 90.6% | 90.6% |
| EBITDA | $0 | -$0 | -$1 | -$0 |
| % Margin | 13.3% | -1.5% | -44.3% | -13.9% |
| Net Income | -$2 | -$1 | -$2 | -$2 |
| % Margin | -61.5% | -40.3% | -96.8% | -53.1% |
| EPS Diluted | -0.03 | -0.018 | -0.037 | -0.027 |
| % Growth | -68.5% | 51.2% | -33.2% | – |
| Operating Cash Flow | $0 | -$3 | $0 | $0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | $0 | -$3 | $0 | $0 |